Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.09)
# 337
Out of 4,829 analysts
226
Total ratings
41.1%
Success rate
14.71%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $3.91 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $17.52 | +59.82% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $103.58 | +44.82% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $110.16 | +38.89% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $10.16 | +37.80% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $32.62 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $20.56 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $9.66 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $35.65 | +62.69% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $31.27 | +37.51% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.13 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.61 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $120.43 | +28.71% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.19 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $14.79 | +136.73% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.03 | +222.58% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.62 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.33 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.45 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.44 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.83 | +42.68% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $33.32 | +50.06% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $2.90 | +72.41% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.41 | +887.65% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.10 | +263.64% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $35.85 | +61.79% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.15 | +9,465.22% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $2.72 | +2,841.18% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.13 | +165.49% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $8.55 | +28.65% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.27 | +91.39% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.34 | +2,549.84% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.24 | +792.86% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $21.34 | +837.05% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.30 | +1,224.50% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.83 | +1,211.48% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.94 | +7,322.68% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.28 | +212.50% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $66.58 | -41.42% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $72.14 | -79.21% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.75 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.01 | +2,895.01% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.91
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $17.52
Upside: +59.82%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $103.58
Upside: +44.82%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $110.16
Upside: +38.89%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $10.16
Upside: +37.80%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $32.62
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.56
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.66
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $35.65
Upside: +62.69%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $31.27
Upside: +37.51%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.13
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.61
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $120.43
Upside: +28.71%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.19
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $14.79
Upside: +136.73%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.03
Upside: +222.58%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.62
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.45
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.44
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.83
Upside: +42.68%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $33.32
Upside: +50.06%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $2.90
Upside: +72.41%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.41
Upside: +887.65%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.10
Upside: +263.64%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $35.85
Upside: +61.79%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.15
Upside: +9,465.22%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $2.72
Upside: +2,841.18%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.13
Upside: +165.49%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $8.55
Upside: +28.65%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.27
Upside: +91.39%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.34
Upside: +2,549.84%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.24
Upside: +792.86%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $21.34
Upside: +837.05%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.30
Upside: +1,224.50%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.83
Upside: +1,211.48%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.94
Upside: +7,322.68%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.28
Upside: +212.50%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $66.58
Upside: -41.42%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $72.14
Upside: -79.21%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.75
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $6.01
Upside: +2,895.01%